Get it on Google Play

FDA approves BESREMi Pen for polycythemia vera treatment

June 26, 2026 9:23 AM EDT Send to a Friend
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), announced that the U.S. Food and Drug Administration has approved ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login